ClinicalTrials.gg
RecruitingNCT05039684Updated Oct 31, 2024

Inflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical Prostaglandins

An observational study in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Glaucoma, Open-Angle with a site in Spain — 6 open to participants now, 9 under way, none of them phase 3. Glaucoma, Open-Angle · Spain.

Planned enrollment
11th of 12
40 · median 198
Started
2021
with 1 other
Observational
12 of 47
2 open now
Registered
39th of 47
by date

Among the 47 studies in Glaucoma, Open-Angle with a site in Spain, this one is the 11th largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2021, is one of 12 observational ones, and was the 39th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

6 of the 47 studies in Glaucoma, Open-Angle with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Glaucoma, Open-Angle with a site in Spain, or all of them as a file.
02

Study summary

Glaucoma is a chronic optic neuropathy whose main modifiable risk factor is an abnormally elevated intraocular pressure. The aim of glaucoma treatment is to slow the progression of the disease by reducing intraocular pressure.

Prostaglandin derivatives are the most effective topical drugs in reducing intraocular pressure (IOP). Among these, latanoprost was the first agent of this type to be approved for use in patients with glaucoma or ocular hypertension.

These eye drops are available with and without preservatives. There are two commercial brands in our environment, Xalatan®, which contains 0.005% latanoprost and 0.2 mg/ml benzalkonium chloride (BAK) and Monoprost®, which contains the same amount of latanoprost but does not carry a preservative. The prostaglandin analog with a lower concentration of active ingredient available in Spain without preservative is tafluprost 0.0015%, commercially available under the name Saflutan®.

The long-term use of hypotensive eye drops with preservatives generates changes in the ocular surface, such as instability of the tear film, conjunctival inflammation, subconjunctival fibrosis, apoptosis of the conjunctival epithelium and deterioration of the corneal surface, causing symptoms such as stinging, tearing, sensation foreign body, photophobia and blurred vision.

This research will evaluate the changes in the ocular surface and in the expression of inflammatory molecules that occur in the conjunctiva in patients with a diagnosis of glaucoma and ocular hypertension who are under ocular hypotensive treatment with tafluprost, comparing it with the two commercial preparations of latanoprost.

These three groups of patients will have a control group of patients with a diagnosis of ocular hypertension who will not have any topical hypotensive medication.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension

Keywords

  • glaucoma
  • prostaglandin
  • ocular hypertension
  • biomarker
  • inflammation
  • confocal in-vivo microscopy
  • cornea
  • tear film
  • conjunctiva
  • impression cytology
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with ocular hypertension or primary open angle glaucoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with primary open angle glaucoma or ocular hypertension as defined in Early Manifest Glaucoma Trial
  • > 18 years old
  • Signed
  • 3 or more months under monotherapy treatment with tafluprost 0.0015%, latanoprost 0.005% with BAK 0.2mg/ml or latanoprost 0.005%.
  • Untreated patients with ocular hypertension must be treatment naïve for the pathology.
  • No presence or history of previous ocular diseases other than glaucoma or ocular hypertension, started before the use of hypotensive medication.

Exclusion criteria

Exclusion Criteria:

  • Ocular surgery in the previous 6 months.
  • Any ocular surface disease not related to inclusion criteria or related issues active within the last 6 months.
  • Any topical treatment other than the evaluated in this study in the last 3 months.
  • In case of artificial teardrops use, only non conservative ones are allowed, with no more than 4 times per day use, and treatment must be suspended 5 days before inclusion.
  • Use of contact lenses in the las 4 weeks.
  • Any mental or physical disease that may prevent performing the required tests for the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
None retained

Groups and cohorts

  • Primary open angle glaucoma / ocular hypertension - Treatment with Xalatan

    Patients with primary open angle glaucoma or ocular hypertension treated with Xalatan

  • Primary open angle glaucoma / ocular hypertension - Treatment with Monoprost

    Patients with primary open angle glaucoma or ocular hypertension treated with Monoprost

  • Primary open angle glaucoma / ocular hypertension - Treatment with Saflutan

    Patients with primary open angle glaucoma or ocular hypertension treated with Saflutan

  • Ocular hypertension - No treatment

    Patients ocular hypertension untreated

06

What researchers measure

Primary outcomes

  1. Inflammatory response in ocular surface secondary to prostaglandin use

    Presence of inflammatory cytokines in ocular surface

    Time frame: 24 hours

  2. Conjunctival cell phenotype and inflammatory infiltration

    Conjunctival cell phenotype assessment by conjunctival in vivo confocal microscopy

    Time frame: 24 hours

  3. Changes in oxidative stress in the tear film

    Changes in oxidative stress at conjunctiva secondary to prostaglandin treatment

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
  • IOBA
    Valladolid, 47011, Spain
    Recruiting
    • Carolina Ossa Calderon, MD, MsC · Contactcossac@ioba.med.uva.es · 983184734
    • Francisco Blazquez Arauzo, MD, MsC · Contactblazquez@ioba.med.uva.es · 983184734
    • Carolina Ossa Calderon, MD · Sub investigator
    • Ramon Juberias Sanchez, MD, PhD · Principal investigator
    • Margarita Calonge Cano, MD, PhD · Sub investigator
    • Yolanda Diebold Luque, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Dec 2025, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Sep 9, 2021
StartActual
Oct 1, 2021
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05039684
Lead sponsor
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Collaborators
Hospital Clínico Universitario de Valladolid
Responsible party
Sponsor
First posted
Sep 9, 2021
Start date
Oct 1, 2021
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 31, 2024

Study contacts

Carolina Ossa Calderon, MD
Contact
cossac@ioba.med.uva.es
983184734
Francisco Blazquez Arauzo, MD, MsC
Contact
blazquez@ioba.med.uva.es
983184734

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion